Infosys staff documents under U.S. scrutiny
MUMBAI (Reuters) - Infosys, India's No. 2 software services exporter, is under scrutiny from the U.S. Department of Homeland Security for likely errors in employer eligibility documents of its staff working in the United States, the company said in a statement.
The Department of Homeland Security (DHS) is reviewing the employer eligibility verifications on Form I-9, said Nasdaq-listed Infosys INFY.O in an April 18 filing on the U.S. Securities and Exchange Commission (SEC).
"In connection with this review, we have been advised that the DHS has found errors in a significant percentage of our Forms I-9 that the Department has reviewed," Infosys said in the SEC filing.
If the DHS concludes that the Forms I-9, used to verify the authorisation of employees to work in the U.S., contains errors it is likely to impose fines and penalties, the company said.
In January, Infosys said it was being investigated in Texas over its sponsorship and use of short-term U.S. business visas.
Jack Palmer, a company employee, has reportedly accused Infosys of misusing the B1 visas to send employees from India to the U.S., its largest export market. Infosys has denied the reports.
Infosys said it could not estimate any loss it might incur from "unfavourable outcomes" related to the ongoing investigation and review.
"In the event that any government undertakes any actions which limit any visa program that we utilize, or imposes sanctions, fines or penalties on us or our employees, this could materially and adversely affect our business and results of operations," the company added.
Infosys, which reported its fiscal fourth quarter earnings on April 13, disappointed investors with weaker-than-expected revenue growth outlook for the fiscal year 2013 due to an uncertain global economy.
The news sent its shares plunging more than 12 percent in their biggest fall in nearly three years and wiped off more than $3 billion from the company's market value.
(Reporting by Aditi Shah. Editing by Jane Merriman)
- Tweet this
- Share this
- Digg this
India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday. Full Article
Top rice exporter India importing over 100,000 T on temporary supply squeeze. Full Article